| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
DSPE-PEG Carboxylic acid does not have a specific biological receptor target. The carboxylic acid group provides a reactive handle for conjugation to amine-containing molecules (e.g., proteins, peptides, targeting ligands) via EDC/NHS coupling chemistry.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG Carboxylic acid sodium is used to form micelles as nanoparticles for drug delivery. The PEG-lipid can be utilized to prepare drug delivery nanoparticles and extends the blood circulation time of liposomes.
|
| ln Vivo |
In vivo, DSPE-PEG Carboxylic acid-containing formulations are used for drug delivery. The PEG component extends the blood circulation time of liposomes and nanoparticles. The carboxylic acid group enables conjugation of targeting ligands for active targeting applications.
|
| Enzyme Assay |
DSPE-PEG Carboxylic acid micelle formation involves dissolving the PEG-lipid in aqueous buffer above its critical micelle concentration. The carboxylic acid group can be activated with EDC/NHS to conjugate amine-containing targeting ligands or drugs. Micelle size and stability are characterized by dynamic light scattering.
|
| Cell Assay |
Cellular uptake and targeting efficacy of DSPE-PEG Carboxylic acid-based nanoparticles are assessed in cell culture. Nanoparticles conjugated to targeting ligands via the carboxylic acid group are added to cells, and uptake is quantified by fluorescence microscopy or flow cytometry. Drug delivery efficiency is measured by assessing the biological activity of encapsulated agents.
|
| Animal Protocol |
In vivo studies involve intravenous administration of DSPE-PEG Carboxylic acid-based formulations in rodent models. Pharmacokinetic parameters such as circulation half-life, tissue distribution, and therapeutic efficacy are evaluated. The PEG component extends circulation time, and targeting ligands can enhance accumulation at target sites.
|
| ADME/Pharmacokinetics |
DSPE-PEG Carboxylic acid sodium extends the blood circulation time of liposomes. The PEG component reduces opsonization and clearance by the mononuclear phagocyte system. The carboxylic acid group enables conjugation of targeting ligands. Pharmacokinetic properties depend on the formulation.
|
| Toxicity/Toxicokinetics |
DSPE-PEG Carboxylic acid sodium is generally considered biocompatible. The DSPE-PEG component has been used in pharmaceutical formulations. Standard safety precautions for handling PEGylated lipids should be followed. No significant toxicity has been reported.
|
| References | |
| Additional Infomation |
DSPE-PEG Carboxylic acid sodium (MW 2000, purity ≥98%) is a PEG-lipid that facilitates the formation of micelle nanoparticles for drug delivery and extends the blood circulation time of liposomes. The carboxylic acid group enables conjugation to targeting ligands or therapeutic agents, making it a valuable tool for drug delivery research.
|
| Molecular Formula |
(C2H4O)NC45H86NO12P.NA
|
|---|---|
| Molecular Weight |
2000(Average)
|
| Exact Mass |
2480.05
|
| CAS # |
1403744-37-5
|
| Appearance |
White to off-white solid powder
|
| SMILES |
[O-]C(=O)CO{-}CC{+n}OCC(=O)NCCOP(O)(=O)OCC(COC(CCCCCCCCCCCCCCCCC)=O)OC(=O)CCCCCCCCCCCCCCCCC.[Na+]
|
| InChi Key |
NIXOVWUDDMBODS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H34N4O5.C29H30N4O4.C29H30N2O3.C27H26N4O5.C25H21F3N4O4/c1-20(2)22-5-7-24(8-6-22)29(36)27-28(35(31(38)30(27)37)26-13-4-21(3)32-33-26)23-9-11-25(12-10-23)40-19-16-34-14-17-39-18-15-34;1-18-4-7-21(8-5-18)27(34)25-26(33(29(36)28(25)35)24-13-6-19(2)30-31-24)20-9-11-22(12-10-20)37-23-14-16-32(3)17-15-23;1-17(2)20-7-11-22(12-8-20)26-25(27(32)23-13-9-21(10-14-23)18(3)4)28(33)29(34)31(26)24-15-6-19(5)30-16-24;1-17-3-12-22(29-28-17)31-24(18-6-10-21(35-2)11-7-18)23(26(33)27(31)34)25(32)19-4-8-20(9-5-19)30-13-15-36-16-14-30;1-14-4-13-19(30-29-14)32-21(15-7-11-18(12-8-15)36-25(26,27)28)20(23(34)24(32)35)22(33)16-5-9-17(10-6-16)31(2)3/h4-13,20,28,36H,14-19H2,1-3H3;4-13,23,26,34H,14-17H2,1-3H3;6-18,26,32H,1-5H3;3-12,24,32H,13-16H2,1-2H3;4-13,21,33H,1-3H3
|
| Chemical Name |
4-[[4-(dimethylamino)phenyl]-hydroxymethylidene]-1-(6-methylpyridazin-3-yl)-5-[4-(trifluoromethoxy)phenyl]pyrrolidine-2,3-dione;4-[hydroxy-(4-methylphenyl)methylidene]-5-[4-(1-methylpiperidin-4-yl)oxyphenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-2,3-dione;4-[hydroxy-(4-morpholin-4-ylphenyl)methylidene]-5-(4-methoxyphenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-2,3-dione;4-[hydroxy-(4-propan-2-ylphenyl)methylidene]-1-(6-methylpyridazin-3-yl)-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyrrolidine-2,3-dione;4-[hydroxy-(4-propan-2-ylphenyl)methylidene]-1-(6-methylpyridin-3-yl)-5-(4-propan-2-ylphenyl)pyrrolidine-2,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
THF: 50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
